BEACON EMR HIPAA Disclaimer Site Map Social Media
BayCare Health System
Community Benefit Financial Assistance Policy Quality Report Card Health Library News Dr.BayCare Find Us
Services Hospitals Find A Doctor Classes & Events About Us Careers Contact Us Get E-Newsletter
HealthDay Articles & Information
 Back  Back


May We Help You?
 

Call 1-877-692-2922
Monday-Friday, 8am to 5pm

Persons with hearing and speech disabilities can reach the above number through TDD and other specialized equipment by calling the Florida Relay Service at 711.

Contact Us
Send 
e-mail
Search jobs


Decrease (-) Restore Default Increase (+) Font Size
Print    Email
Search Health Information   

FDA Approves Generic Versions of Actos

Diabetes drug helps control blood sugar in adults with type 2 disease

FRIDAY, Aug. 17 (HealthDay News) -- The first generic versions of pioglitazone (Actos) have been approved by the U.S. Food and Drug Administration to help adults with type 2 diabetes control blood glucose levels.

License to produce the generic versions in 15 milligrams (mg), 30 mg and 45 mg strengths was granted to Mylan Pharmaceuticals, based in Morgantown, W. Va, the agency said Friday in a news release.

As with the brand name drug, generic versions will contain a label warning that the drug could cause or worsen heart failure in certain people. And there may be an increased risk of bladder cancer in people who take the drug for more than a year, the FDA said.

The most common side effects associated with the drug include cold-like symptoms, headache, sinus infection, muscle pain and sore throat.

Generic versions of FDA-approved drugs are chemically equivalent in strength and quality to their brand-name counterparts, the agency said. Actos is produced by Takeda Pharmaceutical Co.

More information

To learn more about pioglitazone, visit Medline Plus.


Copyright © 2012 HealthDay. All rights reserved.


Serving The Tampa Bay Area © Copyright 2014 BayCare Health System